All In Biotech

Drug Trial Radar · NCT03657043

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

98

Actual

Start

Mar 20, 2019

Primary completion

Feb 8, 2022

Study completion Feb 8, 2022

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
Collaborators
Genmab
First posted
Sep 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

  • tisotumab vedotinDrug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only)Time frame: Up to 28 days
  2. Confirmed Objective Response Rate (ORR) (Part B)Time frame: Up to 9.7 months

Locations

37 sites in 6 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center South Bay

    San Jose, California

  • Poudre Valley Health System (PVHS)

    Fort Collins, Colorado

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Miami Cancer Institute- Plantation (MCIP)

    Miami, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Karmanos Cancer Institute / Wayne State University

    Detroit, Michigan

  • University of Missouri Healthcare / Ellis Fischel Cancer Center

    Columbia, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai Chelsea

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic Fairview Hospital

    Cleveland, Ohio

  • Cleveland Clinic, The

    Cleveland, Ohio

  • Ohio State University Clinical Trials Management Office

    Columbus, Ohio

  • Cleveland Clinic Hillcrest Hospital

    Mayfield Heights, Ohio

  • Texas Oncology - Fort Worth

    Dallas, Texas

  • Renovatio Clinical

    The Woodlands, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Algemeen Ziekenhuis Maria Middelares

    Ghent, Other, Belgium

  • Universitair Ziekenhuis Leuven

    Lueven, Other, Belgium

  • Aalborg Universite Hospital

    Aalborg, Other, Denmark

  • Mater Private

    Dublin, Other, Ireland

  • Cork University Hospital

    Wilton, Other, Ireland

  • Ospedale Ramazzini di Carpi

    Carpi, Other, Italy

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori- IRST S.r.l

    Meldola, Other, Italy

  • Istituto Europeo di Oncologia

    Milan, Other, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Other, Italy

  • Fondazione Policlinico Universitario Agostino

    Rome, Other, Italy

  • Hospital Universitario Vall d'Hebron

    Barcelona, Other, Spain

  • L'Institut Catala d'Oncologia

    L'Hospitalet de Llobregat, Other, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Other, Spain

  • HM Centro Integral Oncologico Clara Campal

    Madrid, Other, Spain

  • Clinica Universidad de Navarra

    Pamplona, Other, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Other, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.